摘要
本文中,我们队免疫乳腺癌的预后和预测标记物中有关癌症微环境的基质组分和免疫参数 的数据进行了总结。由于近期免疫治疗的突破,癌症的宿主免疫应答突显其重要性。目前,在不考虑基质成分重要性的情况下,乳腺癌的分子和临床分型仅仅是依据癌细胞的分子特征。有明显的证据表明浸润免疫和炎症细胞会影响胸腺癌的生物学和临床疗程。然而,免疫细胞的预后和预测功能不同于乳腺癌亚型。三阴性和HER2阳性乳腺癌中预后和预测标志物可以建立和确定免疫参数。 免疫参数也许可以作为临床试验的 多层参数临床决策中的辅助变量。另一方面,最低级、管腔A型乳腺癌中的预后和预测影响是最低的。三阴性乳腺癌和HER2阳性乳腺癌中较高的淋巴细胞浸润和更好的结果(包括更高的化疗敏感度)之间较强联系,也会提高以免疫细胞为靶点增强活性新的治疗方式的选择。免疫标志物具有作为预测性指标的潜力,为病人选择免疫治疗方案(如调定点阻滞剂)。
关键词: 乳腺癌,宿主因素,免疫细胞,免疫调节点,免疫治疗,预后,肿瘤浸润淋巴细胞
图形摘要
Current Cancer Drug Targets
Title:The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Volume: 15 Issue: 8
Author(s): Thomas Karn, Lajos Pusztai, Achim Rody, Uwe Holtrich and Sven Becker
Affiliation:
关键词: 乳腺癌,宿主因素,免疫细胞,免疫调节点,免疫治疗,预后,肿瘤浸润淋巴细胞
摘要: In this paper, we will review the data on stromal components and immunological parameters in the cancer microenvironment as prognostic and predictive markers in breast cancer. Host immunological response to cancer has gained importance because of recent breakthroughs in immunotherapy. Currently, molecular and clinical subtyping of breast cancer is solely based on the molecular features of the cancer cells without considering the importance of stromal components. There is now clear evidence that infiltrating immune and inflammatory cells influence the biology and clinical course of breast cancer. However, the prognostic and predictive function of immune cells differs between breast cancer subtypes. Immune parameters are established and validated prognostic and predictive markers in triple negative and for HER2 positive breast cancers and may be ready to be used as stratification parameters in clinical trials and as adjunct variables when making clinical decisions. On the other hand, the prognostic and predictive impact is minimal in low grade, luminal A type breast cancers. The strong association between higher lymphocytic infiltration and better outcome (including greater chemotherapy sensitivity) in TNBC and HER2 positive cancers also raises novel therapeutic options that target immune cells to increase their activity. Immune markers also carry the potential to serve as predictive markers to select patients for immunotherapeutic regimens (e.g. checkpoint inhibitors).
Export Options
About this article
Cite this article as:
Thomas Karn, Lajos Pusztai, Achim Rody, Uwe Holtrich and Sven Becker , The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers, Current Cancer Drug Targets 2015; 15 (8) . https://dx.doi.org/10.2174/156800961508151001101209
DOI https://dx.doi.org/10.2174/156800961508151001101209 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis of New Curcumin-like Pentadienones by O- and C-glycosylation
Current Organic Chemistry Substitution at Phenyl Rings of Chalcone and Schiff Base Moieties Accounts for their Antiproliferative Activity
Anti-Cancer Agents in Medicinal Chemistry 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Targeting Cancer using Curcumin Encapsulated Vesicular Drug Delivery Systems
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Aptamers Against Cell Surface Receptors: Selection, Modification and Application
Current Medicinal Chemistry Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Editorial (Thematic Issue: <i>In Silico</i> Drug Design and Medicinal Chemistry)
Current Topics in Medicinal Chemistry Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals Prognostic and Predictive Markers in Colorectal Cancer – The Role of New Genomic Technologies
Current Pharmacogenomics Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology